Evidence map›Paper›PMID 39908169›Full record

ArticleCancer medicine2025

Trends in the Incidence and Survival Outcomes in Patients With Small Cell Lung Cancer in the United States: An Analysis of the SEER Database.

Dipesh Uprety, Randell Seaton, Abesh Niroula, Tarik Hadid, Kaushal Parikh, Julie J Ruterbusch

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dipesh UpretyDepartment of Medical Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.ORCID https://orcid.org/0000-0002-4278-9703
Randell SeatonPopulation Studies and Disparities Research Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.
Abesh NiroulaWinship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Tarik HadidDepartment of Medical Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.
Kaushal ParikhMayo Clinic, Rochester, Minnesota, USA.
Julie J RuterbuschPopulation Studies and Disparities Research Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere has been a lack of updated epidemiological data on the incidence and survival outcomes for patients with small cell lung cancer (SCLC) in the United States over the last two decades.

methodsA retrospective, population-based study was conducted utilizing the Surveillance, Epidemiology, and End Results (SEER) program to identify patients with SCLC from 2000 to 2020. Trends in cancer incidence, incidence-based mortality rates, 1-year relative survival rates and 1-year observed survival were evaluated utilizing the SEER database.

resultsThe database identified a total of 188,426 SCLC patients during the study period from 2000 through 2020. The age-adjusted incidence rate slowly declined, on average, by 3% (95% CI: -3.2% to -2.8%) each year from 9 per 100,000 in 2000 to 4.6 per 100,000 in 2020. The decline is evident for all age groups, sexes, and races. Incidence-based mortality also declined slowly from 6.6 in 2005 to 3.5 in 2020. However, survival outcomes, including 1-year relative survival and 1-year observed survivals, have not improved significantly over the last two decades.

conclusionThis study found that the incidence of SCLC has decreased from 2000 to 2020, likely due to a reduction in smoking rates, underscoring the importance of smoking abstinence. An improvement in incidence-based mortality is likely related to an enhanced medical care and a decrease in the incidence of SCLC, but the lack of improvement in survival outcomes reflects the need for more effective systemic therapy.

Indexed as

Lung NeoplasmsSmall Cell Lung CarcinomaAdultAgedAged, 80 and overFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesSEER ProgramSurvival RateUnited StatesYoung Adultepidemiologylung cancerpopulationSCLCSEERsmall‐cell

Identifiers

PMID39908169
PMCPMC11797299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.